BACKGROUND: The available evidence in locally advanced rectal cancer (LARC) suggests a low prevalence of deficient mismatch repair (dMMR) protein status, approximating 1-3%. METHODS: Patients with LARC who were offered long course chemoradiation (LCRT), as per institution protocol during the period of 1st January 2014 to 31st December 2015 at Tata Memorial Hospital (TMH) in Mumbai were evaluated for outcomes and assessment of MMR status. RESULTS: A total of 419 patients were evaluated for LARC in TMH, of whom 354 were treated with LCRT. Of these 354 patients, 296 were assessable for MMR status based on tissue adequacy for testing. Three patients (1.01%) has dMMR status, while the remaining 293 patients had proficient MMR status. A total of 240 patients (67.8%) underwent curative intent resections. With a median follow-up of 32 months, estimated 3-year recurrence free survival (RFS) and overall survival (OS) for the resected group was 63.5% and 85.2%, respectively, while 3-year event free survival and OS for the unresected cohort was 15.2% and 15.8%, respectively. Signet ring histology, higher ypT stage, involved margin status post resection, and delays (>1 week) in LCRT were associated with inferior OS on multivariate analysis. CONCLUSIONS: In a large LARC cohort, a majority of tumors had proficient MMR status, suggesting that MSI as a biomarker may have limited applicability in the management of rectal cancers. Signet ring histology, CRM involvement post resection, higher ypT stage and interruptions in LCRT predicted for inferior OS.
BACKGROUND: The available evidence in locally advanced rectal cancer (LARC) suggests a low prevalence of deficient mismatch repair (dMMR) protein status, approximating 1-3%. METHODS: Patients with LARC who were offered long course chemoradiation (LCRT), as per institution protocol during the period of 1st January 2014 to 31st December 2015 at Tata Memorial Hospital (TMH) in Mumbai were evaluated for outcomes and assessment of MMR status. RESULTS: A total of 419 patients were evaluated for LARC in TMH, of whom 354 were treated with LCRT. Of these 354 patients, 296 were assessable for MMR status based on tissue adequacy for testing. Three patients (1.01%) has dMMR status, while the remaining 293 patients had proficient MMR status. A total of 240 patients (67.8%) underwent curative intent resections. With a median follow-up of 32 months, estimated 3-year recurrence free survival (RFS) and overall survival (OS) for the resected group was 63.5% and 85.2%, respectively, while 3-year event free survival and OS for the unresected cohort was 15.2% and 15.8%, respectively. Signet ring histology, higher ypT stage, involved margin status post resection, and delays (>1 week) in LCRT were associated with inferior OS on multivariate analysis. CONCLUSIONS: In a large LARC cohort, a majority of tumors had proficient MMR status, suggesting that MSI as a biomarker may have limited applicability in the management of rectal cancers. Signet ring histology, CRM involvement post resection, higher ypT stage and interruptions in LCRT predicted for inferior OS.
Entities:
Keywords:
Mismatch repair (MMR); immunohistochemistry (IHC); neoadjuvant long course chemoradiation (NACTRT); rectal adenocarcinoma; signet ring
Authors: Wade S Samowitz; Karen Curtin; Roger K Wolff; Sheryl R Tripp; Bette J Caan; Martha L Slattery Journal: Cancer Causes Control Date: 2009-08-11 Impact factor: 2.506
Authors: Gordon Hutchins; Katie Southward; Kelly Handley; Laura Magill; Claire Beaumont; Jens Stahlschmidt; Susan Richman; Philip Chambers; Matthew Seymour; David Kerr; Richard Gray; Philip Quirke Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger Journal: N Engl J Med Date: 2003-07-17 Impact factor: 91.245
Authors: P Mathur; J J Smith; C Ramsey; M Owen; A Thorpe; S Karim; C Burke; S Ramesh; P M Dawson Journal: Colorectal Dis Date: 2003-09 Impact factor: 3.788
Authors: Marloes Swets; Cristina Graham Martinez; Shannon van Vliet; Arjan van Tilburg; Hans Gelderblom; Corrie A M Marijnen; Cornelis J H van de Velde; Iris D Nagtegaal Journal: Histopathology Date: 2022-07-14 Impact factor: 7.778
Authors: Chiara Dalle Fratte; Silvia Mezzalira; Jerry Polesel; Elena De Mattia; Antonio Palumbo; Angela Buonadonna; Elisa Palazzari; Antonino De Paoli; Claudio Belluco; Vincenzo Canzonieri; Giuseppe Toffoli; Erika Cecchin Journal: Oncol Res Date: 2021-06-09 Impact factor: 5.574